RecruitingPhase 1NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

Sponsor

Nurix Therapeutics, Inc.

Enrollment

345 participants

Start Date

Sep 29, 2021

Study Type

INTERVENTIONAL

Conditions

Gastric Cancer Non-small Cell Lung Cancer (NSCLC)Head and Neck Squamous Cell Carcinoma Ovarian Cancer, Epithelial GastroEsophageal Junction (GEJ) Cancer Metastatic or Unresectable Melanoma Metastatic Castration-resistant Prostate Cancer (mCRPC)Malignant Pleural Mesothelioma (MPM)

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing NX-1607, a new investigational drug that targets a protein regulating immune activity, in adults with advanced solid tumors or blood cancers that have progressed despite prior treatments. **You may be eligible if...** - You are 18 years or older - You have a solid tumor or blood cancer that has spread or cannot be surgically removed - You have already received standard treatment options, are not eligible for them, or cannot access them - You are in good general health (ECOG performance status 0–1) - At least 3 weeks have passed since your last cancer therapy (or 2 weeks since last radiation) **You may NOT be eligible if...** - Your last cancer treatment was too recent (under 3 weeks, or under 2 weeks for radiation) - You have active symptomatic brain metastases - You have serious uncontrolled health conditions or active infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNX-1607

Oral NX-1607

DRUGPaclitaxel

Paclitaxel IV

Locations(17)

City of Hope

Duarte, California, United States

University of Southern California

Los Angeles, California, United States

University of California, San Francisco

San Francisco, California, United States

University of Colorado School of Medicine

Aurora, Colorado, United States

University of Chicago

Chicago, Illinois, United States

University of North Carolina

Chapel Hill, North Carolina, United States

University of Oklahoma

Oklahoma City, Oklahoma, United States

MD Anderson Cancer Center

Houston, Texas, United States

University of Virginia

Charlottesville, Virginia, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

Royal Marsden Hospital NHS Foundation Trust

Sutton, Surrey, United Kingdom

Addenbrookes Cambridge University Hospital

Cambridge, United Kingdom

Beatson West of Scotland Cancer Centre

Glasgow, United Kingdom

Sarah Cannon Research Institute

London, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom

Northern Centre for Cancer Care

Newcastle, United Kingdom

Churchill Hospital

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05107674

Related Trials

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT0714001615 locations

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

NCT045579691 location

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT0630524712 locations

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497254 locations